Microencapsulated iNOS-expressing cells cause tumor suppression in mice

Area of Science:

• Biomedical Engineering
• Cancer Biology
• Immunology

Background:

• Macrophages eliminate tumor cells via nitric oxide (NO) and reactive nitrogen species (RNS) upon inducible nitric oxide synthase (iNOS) gene upregulation.
• Developing targeted cancer therapies that leverage immune cell functions is a key research area.

Purpose of the Study:

• To develop novel, controllable iNOS-expressing human cell lines for cancer therapy.
• To evaluate the efficacy of encapsulated iNOS-expressing cells for tumor destruction in vivo.

Main Methods:

• Engineered two human cell lines to express iNOS under inducible control (ecdysone or tetracycline analogues).
• Encapsulated iNOS-expressing cells in alginate-poly-L-lysine membranes for tumor site delivery.
• Administered inducers (ponasterone A, muristerone A, or doxycycline) to activate iNOS and NO/RNS production in encapsulated cells within a nude mouse model.
• Assessed tumor killing efficacy against human ovarian (SKOV-3) and colon (DLD-1) cancer xenografts.
• Analyzed the role of Fas/FasL protein upregulation in tumor cell death.

Main Results:

• Encapsulated iNOS-expressing cells successfully generated high concentrations of NO and RNS at tumor sites upon induction.
• Complete eradication (100%) of human ovarian cancer SKOV-3 tumors was achieved.
• Significant tumor reduction (54%) was observed in human colon cancer DLD-1 models.
• Tumor killing correlated with the upregulation of Fas/FasL proteins in the iNOS-expressing cells.

Conclusions:

• Encapsulated, inducible iNOS-expressing cells represent a promising strategy for targeted cancer therapy.
• This approach demonstrates effective tumor cell killing, particularly in ovarian cancer models, via NO/RNS release and Fas/FasL pathway activation.
• Further research into optimizing delivery and induction protocols could enhance therapeutic outcomes for various cancers.